Pharmaceutical commercialization has never been more complex, but complexity is not the core issue. Brent Herspiegel, CEO of Acumetis, says the bigger challenge is making sound decisions amid uncertainty. Despite unprecedented access to data and expertise, organizations often struggle to make timely choices that remain effective across launch scenarios.
In the interview, Herspiegel explains that Acumetis was built as an integrated commercialization firm, bringing launch strategy, medical, market access and analytics together under one roof. Rather than optimizing each function in isolation, the company focuses on connecting interdependent workstreams early, before misaligned decisions create downstream risk. He says that model helps companies plan for real-world variability, including shifts in launch timing that can alter results.
Looking ahead, Herspiegel says future winners will be defined by their ability to act decisively with imperfect information. Success will favor organizations willing to challenge assumptions, rethink legacy launch models and align strategy with execution from end to end. For pharmaceutical leaders navigating uncertainty, the conversation offers a clear view of what it takes to reduce launch risk and expand what is possible in commercialization.
The editorial staff had no role in this post's creation.